Research ArticleHot Topics
FAP: The Next Billion Dollar Nuclear Theranostics Target?
Jeremie Calais
Journal of Nuclear Medicine February 2020, 61 (2) 163-165; DOI: https://doi.org/10.2967/jnumed.119.241232
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California
2Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California
3Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; and
4Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 2
February 1, 2020
FAP: The Next Billion Dollar Nuclear Theranostics Target?
Jeremie Calais
Journal of Nuclear Medicine Feb 2020, 61 (2) 163-165; DOI: 10.2967/jnumed.119.241232
Jump to section
Related Articles
Cited By...
- Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
- One Hundred Years of the Tracer Principle
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
- Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
- Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
- The Annual Journal Impact Factor Saga
- An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
- Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year